Overview
Manuel Marina Breysse is cardiologist, chief executive officer, and co-founder of Idoven, per the company our-team page. Idoven is building a healthier world in which no cardiovascular disease goes undiagnosed or untreated — applying AI to electrocardiogram and cardiologic data analysis. The team page describes Idoven as engineers, cardiologists, scientists, and business leaders on a mission.
Idoven reports GDPR compliance and ISO 27001 certification per footer disclosures on idoven.ai reviewed 2026 — regulatory credentials European hospital buyers require for clinical AI procurement.
Role and company
As CEO and Co-Founder, Breysse leads Idoven alongside co-founder José María Lillo, chief scientific officer, and executives including chief legal officer Isabel Sierra and chief technical officer Tomás Pérez per the team page. Idoven serves medtech, life sciences, and preventative screening programs with cardiologic intelligence software.
Idoven announced AstraZeneca partnership launching CONCERTO to advance early amyloidosis diagnosis per a site banner reviewed 2026 — a pharma collaboration extending Breysse’s clinical AI into therapeutic patient identification workflows.
Background and career context
Idoven our-team page identifies Breysse as Cardiologist, CEO and Co-Founder without listing prior hospital appointments or academic affiliations on the cited biography reviewed July 2026. His cardiologist credential distinguishes Idoven among cardiovascular AI companies led by software entrepreneurs without clinical practice backgrounds.
Breysse’s CEO-scientist pairing with CSO co-founder Lillo combines clinical cardiology and scientific research leadership — a structure common in European health-tech spinouts.
Company-building or leadership context
Breysse co-founded Idoven to bring cardiologic intelligence to software products spanning medtech integrations, life sciences trials, and preventative screening. Idoven’s medical advisors include Prof. Gregory Y. H. Lip of University of Liverpool and Dr. Pablo García Pavía of Hospital Puerta del Hierro and CNIC per team page — giving clinical validation networks across UK and Spanish cardiology centers.
Investor backing from Insight Partners and Northzone per team page footer supports Breysse’s scale from Spanish startup to multinational cardiovascular AI vendor.
Public milestones
Breysse is Cardiologist, CEO and Co-Founder on idoven.ai/our-team reviewed July 10, 2026. AstraZeneca CONCERTO partnership for early amyloidosis diagnosis announced on Idoven site. ISO 27001 and GDPR compliance certifications displayed on official site.
Idoven markets preventative screening and pre-initiation ECG testing for pharma on product pages reviewed 2026.
Why their work matters
Idoven under Breysse tests whether AI ECG analysis can integrate into medtech devices, pharma screening, and health-system workflows across European regulatory environments — where GDPR and ISO certifications gate hospital adoption. Cardiologist CEO leadership gives clinical credibility when Idoven partners with AstraZeneca on amyloidosis early diagnosis.
For healthcare AI readers, Idoven competes with Anumana and Eko in cardiovascular signal AI but emphasizes European medtech and pharma integration paths.
Sources and references
Primary sourcing: Idoven our-team page, reviewed July 10, 2026.
- Idoven — Our Team (idoven.ai)
Cardiologist CEO co-founder title from official team page. AstraZeneca partnership from Idoven site banner.
Idoven site markets building healthier world where no cardiovascular disease goes undiagnosed or untreated — mission Breysse advances as cardiologist CEO with GDPR and ISO 27001 certified platform per site footer. AstraZeneca CONCERTO partnership banner for early amyloidosis diagnosis illustrates Breysse’s clinical AI reaching pharma patient identification workflows beyond standalone medtech device integrations.
Idoven team includes co-founder CSO José María Lillo, CLO Isabel Sierra, CTO Tomás Pérez, and VP Growth Pedro Botija per our-team page — executive depth Breysse assembled for European cardiovascular AI scale. Medical advisors Prof. Gregory Y. H. Lip and Dr. Pablo García Pavía provide UK and Spanish cardiology validation networks supporting Breysse’s clinical credibility.